FDG PET imaging in the evaluation of post-transplant lymphoproliferative disorder following renal transplantation.
OBJECTIVE
To assess the usefulness of fluorodeoxyglucose positron emission tomography (FDG PET) in the evaluation of post-transplant lymphoproliferative disorder (PTLD) following renal transplantation.


METHODS
Staging FDG PET examinations were reviewed in five patients with biopsy proven post-renal allograft PTLD and compared with conventional imaging. Follow-up PET examinations of three patients at various points during their therapy for PTLD were also reviewed and compared with clinical outcome.


RESULTS
PET imaging identified all disease sites seen at cross-sectional imaging, clarified sites of uncertain significance and detected additional disease in two out of five patients. Early follow-up imaging impacted PTLD management in two of three patients.


CONCLUSIONS
In this limited series FDG PET was an effective imaging modality in the staging and follow-up of PTLD.
O'Conner
Angus R
AR
Department of Radiology, Nottingham City Hospital, UK.
Franc
Benjamin L
BL
D000293:Adolescent; D000328:Adult; D001706:Biopsy; D002648:Child; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000494:pharmacology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D016030:Kidney Transplantation / Q000009:adverse effects*; D008232:Lymphoproliferative Disorders / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology*; D008297:Male; D049268:Positron-Emission Tomography; D011183:Postoperative Complications; D019275:Radiopharmaceuticals / Q000494:pharmacology; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed; D014915:Whole-Body Counting
D007166:Immunosuppressive Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18